The Liposome Company Inc. regulatory update

The FDA granted Orphan Drug Designation for LIPO's TLC C-53 liposomal prostaglandin E1 to treat acute respiratory distress syndrome (ARDS). LIPO expects to conclude a Phase III trial of TLC C-53 in the first half of 1997. ...